North America Novel Drug Delivery Systems (NDDS) Market - Segmented by Route of Administration, Mode of NDDS, and Geography -Growth, Trends, and Forecast (2020 - 2025)

Looking to buy the report?

The North America novel drug delivery systems market is expected to witness a CAGR of 8.7% during the forecast period, 2018-2023. There is continuous growth in the market for drug delivery systems, which will continue to grow at an impressive rate during the forecast period as well.

Requirement of Controlled Release of Drugs

The method by which a drug is delivered can have significant influence on its efficacy. Most of the drugs have an optimum concentration range and requirement of controlled release of drugs in the body. Concentrations above or below the prescribed range can be toxic or can produce no therapeutic benefits. Transdermal patches, implants, nasal systems, microcapsules, etc., are some of the common systems that are considered under the controlled release systems. Hence, the requirement of controlled release of drugs drives the novel drug delivery systems market.

The other factors include advancement in pharmacology promoting increased adoption of novel drug delivery systems (NDDS) and technological advancements promoting the development of NDDS.

Stability Issues

The stability of a delivery system is one of the most important factors that affects the drug delivery systems market. Liposomes are the most common nanocarriers for drug delivery, owing to the several advantages they offer over other delivery systems. Liposomes help in stabilizing therapeutic compounds and improved bio distribution of compounds to target sites in-vivo. However, stability of liposome-based drug delivery systems is a major concern, which is restraining the growth of this market. The other restraining factors include stringent regulatory guidelines and product recalls.

US is leading the Market

The United States is leading the market since many years and is expected to continue the trend. Some of the novel drugs that were FDA approved in 2016 include Axumin, Lartruvo, and Tecentriq. These are the new advancements that have been taken place in the market recently. Also, the advancements in pharmacology and increasing adoption of NDDS are expected to drive the US novel drug delivery systems market during the forecast period.


Key Developments in the Market

  • December 2017: FDA approved new Type 2 diabetes drug from Merck and Pfizer.
  • March 2017: Sanofi and Regeneron announced FDA approval of Dupixent (dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis.

Major Players: Abbott Laboratories, AstraZeneca PLC, Bayer Healthcare Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Roche Holding AG, and Sanofi SA, among others

Reasons to Purchase the Report

  • Current and future novel drug delivery systems market outlook in the developed and emerging markets
  • Analyzing various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3-month analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report

  • This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Our clients include:


Looking to Customize Report?

Please Enter Email ID

Please Enter Message